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Interferon Regulatory Factor 5 (IRF5) is one of nine members of the IRF family of
transcription factors. Although initially discovered as a key regulator of the type I
interferon and pro-inflammatory cytokine arm of the innate immune response, IRF5 has
now been found to also mediate pathways involved in cell growth and differentiation,
apoptosis, metabolic homeostasis and tumor suppression. Hyperactivation of IRF5 has
been implicated in numerous autoimmune diseases, chief among them systemic lupus
erythematosus (SLE). SLE is a heterogeneous autoimmune disease in which patients
often share similar characteristics in terms of autoantibody production and strong
genetic risk factors, yet also possess unique disease signatures. IRF5 pathogenic alleles
contribute one of the strongest risk factors for SLE disease development. Multiple models
of murine lupus have shown that loss of Irf5 is protective against disease development.
In an attempt to elucidate the regulatory role(s) of IRF5 in driving SLE pathogenesis, labs
have begun to examine the function of IRF5 in several immune cell types, including B
cells, macrophages, and dendritic cells. A somewhat untouched area of research on
IRF5 is in T cells, even though Irf5 knockout mice were reported to have skewing of
T cell subsets from T helper 1 (Th1) and T helper 17 (Th17) toward T helper 2 (Th2),
indicating a potential role for IRF5 in T cell regulation. However, most studies attributed
this T cell phenotype in Irf5 knockout mice to dysregulation of antigen presenting cell
function rather than an intrinsic role for IRF5 in T cells. In this review, we offer a different
interpretation of the literature. The role of IRF5 in T cells, specifically its control of T cell
effector polarization and the resultant T cell-mediated cytokine production, has yet to
be elucidated. A strong understanding of the regulatory role(s) of this key transcription
factor in T cells is necessary for us to grasp the full picture of the complex pathogenesis
of autoimmune diseases like SLE.
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INTRODUCTION

autoimmune disease conditions, among them RA, SLE, MS,
type 1 diabetes mellitus, idiopathic thrombocytopenic purpura,
and experimental allergic encephalomyelitis (1, 2, 13–19).
Th1 cells are traditionally defined by their production of IL-2
and IFN-γ and by expression of the transcription factor and
epigenetic modifier, T-bet, a member of the T-box family
of transcription factors (20–22). In the subsequent decades
following the initial characterization of these defining factors,
critical roles for the DNA-binding regulatory proteins signal
transducer and activator of transcription 4 (STAT4), STAT1,
and STAT5 in the development and support of Th1 subsets
have also been revealed (23, 24). Briefly, naïve CD4+ T cells
are stimulated to develop into Th1 effector cells by IL-12
binding to the IL-12 receptor (23, 25). Once activated, Th1
cells produce IL-2 and IFN-y. IL-2 acts as a potent inducer of
both T cell proliferation and T cell effector fate decision (26).
IFN-y employs both stimulatory and inhibitory roles to maintain
Th1 effector dominance. IFN-y can induce the phosphorylation
of STAT1, thereby increasing expression of the Th1 specific
genes, IL-12 receptor beta 1 (IL12RB) and T-box transcription
factor 21 (TBX21; encoding T-bet). Increased levels of T-bet
results in positive feedback on T-bet expression through T-bet
activation of IFNG transcription. T-bet also increases STAT1
activation and mediates the upregulation of Th1-specific genes
including IL12R, which will in turn signal to increase STAT4
phosphorylation and dimerization. STAT4 itself can act as a
potent transcriptional repressor of genes that would normally
support Th2 differentiation (i.e., GATA3) and acts in concert
with T-bet to promote the positive feedback loop resulting in
increased IFN-γ production.
This feedback loop enhancing Th1 differentiation also has
built in inhibitory mechanisms. T-bet can bind to and inhibit
BCL-6 (B-cell lymphoma 6 protein) early in Th1 polarization,
preventing transcription of genes involved in alternative effector
fates (27). T-bet and BCL-6 comprise two lineage-defining
factors that cooperate in the regulation of Th1 gene expression
patterns (28). However, later in Th1 activation T-bet recruits
BCL-6 to the IFNG promoter, resulting in inhibition of IFNG
transcription and thereby shutting down one of the main
drivers of the Th1 effector response (23, 28, 29). In addition,
T-bet increases the transcription of the membrane protein T
cell immunoglobulin mucin-3 (Tim-3) in later stages of Th1
differentiation, which acts as an inhibitor of the Th1 response
upon binding to the ligand, β-galactosidase-binding lectin 9
(Gal-9) (30, 31). Gal-9 regulates Th-induced proinflammatory
cytokine production (32). Further supporting the concept that
dysregulation of T-bet can result in a pathologically imbalanced
immune system, Tim-3 blockade has been shown to result in
autoimmune disease development (33). Interestingly, most of
T-bet’s transcriptional regulatory capabilities have been shown
to occur through epigenetic modifications of genetic loci using
either H3K4 (activating) or H3K27me3 (inactivating) chromatin
methylation patterns. In fact, production of the key Th1 driving
cytokine IFN-γ is dependent on both chromatin remodeling
by T-bet and increased IL-12R expression through direct Tbet transcriptional activity (29, 34–36). However, much less has
been published with regards to the direct negative regulation of

T cells are responsible for balancing a variety of regulatory
and effector functions. Many of these roles are accomplished
through the expression of a panel of cytokines controlled
by a specific cohort of transcription factors. These cytokines
can act to initiate, support or inhibit different T cell effector
functions and, during homeostatic conditions, maintain a tight
immunological balance between pro- and anti-inflammatory T
cell functions. In the case of immune-mediated diseases, the
balance between T cell subsets is often disrupted. For instance,
patients with systemic lupus erythematosus (SLE) demonstrate
an increase in T helper 1 (Th1) relative to T helper 2 (Th2)
cells and a dysregulated balance between Th1 and T helper
17 (Th17) cells, while results from single cell sequencing of
patients with rheumatoid arthritis (RA) have demonstrated a
skewing toward Th1 effector memory CD4+ T cells, and a
murine model of multiple sclerosis (MS) showed resistance to
disease development due, in part, to a loss of key T cell intrinsic
Th1 mediators (1–4). In SLE studies performed in humans
and mice, some of the likely cytokine inflammatory mediators
and immunomodulatory agents identified as participating in
disease development include (but are not limited to) interferon
(IFN)-α, IFN-γ, tumor necrosis factor (TNF), interleukin (IL)1, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, IL21 and transforming growth factor (TGF)-β (5–8). Although
many of these cytokines are produced by various antigen
presenting cells (APCs) to help initiate effector T cell responses,
all of these cytokines are also produced in varying quantities
by the effector T cells themselves. Sustained T cell response,
both appropriate and pathogenic following the initial priming
event, depends greatly on the ability of the T cells to
both produce the appropriate cytokines and reformat their
transcriptional landscape at an epigenetic level to generate a
positive feedback loop. Dysregulation of this positive feedback
loop or inappropriate epigenetic reprogramming could result
in a T cell-driven dysregulation of pro- or anti-inflammatory
cytokine production, as seen in numerous autoimmune diseases
(9–11). This review will delve specifically into the potential
roles for IRF5 in the regulation of effector T cell decision and
maintenance with a focus on Th1, Th2 and Th17 subsets, whose
high interconnectivity has been demonstrated to be impacted by
IRF5 deletion or hyperactivation. However, continued research
into a potential role(s) for IRF5 in the other T cell subsets,
particularly follicular helper T (Tfh) cells and regulatory T (Treg)
cells, is an important next step in the elucidation of autoimmune
disease pathogenesis via IRF5 dysregulation. For a more general
review on the role of cytokines in autoimmune disease, see
Raphael et al. (12).

Th1 Cells
Th1 effector cells regulate the body’s defense against viruses,
bacteria and intracellular pathogens and, when properly
functional, are vital members of the immunological homeostasis
required to maintain our health. However, dysregulation
of Th1 cells has been implicated as a key player in the
global immunological dysfunction that results in many
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T-bet activity in activated Th1 cells and how dysregulation at the
level of T-bet could result in rampant Th1 activation and the
development of autoimmune disease.
As previously described, T-bet clearly plays an indispensable
role in the positive feedback loop governing Th1 effector
subset polarization. T-bet both positively regulates ∼50% of
Th1-specific genes and inhibits Th2-specific gene transduction,
including GATA3, the Th2-specific transcription factor (29).
Interestingly, ∼70% of Th2-specific genes in Th1 cells are still
bound by GATA3. In this scenario, GATA3 is bound by T-bet
and inhibited from transducing Th2-specific transcripts in Th1
effector cells (37, 38). Other sources show that T-bet can also
directly interact with and recruit GATA3 away from its Th2 gene
loci. In either case, it is hypothesized that part of the rationale for
skewing toward a Th2 phenotype upon loss of negative regulation
by TBX21 is due to both increased GATA3 transcription and
increased GATA3 association with Th2-specific genetic loci (29).

(46, 48). In naïve CD4+ T cells, the predominant SWEF family
member expressed is DEF6 (47). As in ABCs, the importance
of DEF6 as a master regulator has become increasingly evident
through continuing discoveries of its roles in many aspects
of T cell regulation, including IRF4 modulation, cytoskeletal
kinetics and protein expression control through mammalian
target of rapamycin complex 1 (mTORC1) regulation (49–53). In
addition, as also observed in ABCs, upon T cell stimulation IRF5
levels are shown to dramatically increase (43, 54). If a similar
pattern is followed in T cells as in ABCs, elevated levels of IRF5
may allow it to escape inhibition by DEF6 and perform its crucial
regulatory role(s) in T cells (Figure 1).
So what regulatory role(s) might IRF5 play in Th1 cells?
Upon stimulation of ABCs with IFN-γ and IL-21, levels of
IRF5 increase, thereby allowing IRF5 to escape its negative
regulation by SWEF family members, translocate to ABC
transcriptional sites, and recruit T-bet to ABC-specific T-bet
binding motifs (46, 55). It would be interesting to examine
if this similar chromatin remodeling by T-bet followed by
transcriptional activation resulting specifically from IRF5 driven
T-bet recruitment in ABCs is a conserved mechanism for
epigenetic and transcriptional regulation in T cells. In this
scenario, IRF5 deletion would also likely result in GATA3 release
from T-bet, allowing increased GATA3 translocation and binding
to Th2-specific cytokine promoters, resulting in increased Th2specific genes and cytokines (Figure 1). A mechanism similar
to this one has already been alluded to in the Irf5−/− pristaneinduced model of lupus, where loss of Irf5 results in an increase
in the production of the Th2-specific cytokines IL-4 and IL-5
(41, 42, 56).
The proposed inclusion of IRF5 in the regulation of T-bet
through a conserved interaction with DEF6 in T cells will likely
have direct implications in our understanding of the control of
cytokine release by T cells and the T cell-driven pathogenesis of
several autoimmune diseases. An example of this is regulation of
the runt-related transcription factor 3 (RUNX3) gene. RUNX3
enhances IFN-γ production and inhibits IL-4 production when
recruited to the promoter regions by its interaction with T-bet
or other members of the T-bet family. Upon Th1 activation,
RUNX3 has been shown to be transcriptionally activated by Tbet. RUNX3 will then form a complex with T-bet and translocate
to the promoters of IFN-γ and IL-4, activating and inhibiting
their transcription, respectively, to maintain the Th1 positive
feedback loop. Our hypothesis is that T-bet recruitment to sites
of transcriptional regulation is mediated by IRF5 (Figure 1).
In a 2016 paper examining effects of Runx3 polymorphisms,
they identified an IRF4 binding site upstream of the Runx3
promoter (57). In 2019, this same group identified that this
area in the promoter region could also mediate binding of
other transcription factors, including IRF5 (57). Loss of Runx3
compromises IFN-γ production and abrogates inhibition of IL-4,
thereby implying a vital role for RUNX3 in maintaining effector
T cell polarization (58, 59).
Many key regulatory signaling and transcriptional proteins
are expressed in both B and T cells. If IRF5 is indeed required
to recruit T-bet to its transcriptional loci, loss of IRF5 would
result in decreased efficiency of T-bet initiation of its Th1

A Conserved DEF6-IRF5-T-bet Regulatory
Axis Mediates Th1 Effector Response
Through T-bet
Th1 cells are capable of producing the cytokines granulocyte
macrophage colony stimulating factor (GM-CSF), IL-2, TNF-β,
and IFN-γ (39). As previously described, uncontrolled positive
feedback of these cytokines on T cells can result in an imbalance
between T cell subsets and their secreted cytokines, resulting in
the development of autoimmune disease pathologies (40). Here
we will explore the role of IRF5 in regulating an appropriate Th1
immune response and how loss of IRF5 may cause effector T
cell dysregulation.
In the full-body Irf5 knockout (KO) mouse, the majority
of studies have shown that there is skewing of T cells toward
a Th2 effector phenotype with an accompanying decrease in
Th1 effector subsets, thereby implicating a role for IRF5 in
Th1 effector T cell commitment and/or maintenance (41–
44). However, the T cell intrinsic IRF5-dependent molecular
and genetic systems at play in these regulatory mechanisms
governing Th1 feedforward and inhibitory loops have yet to
be thoroughly explored. Based on previously published work,
it seems likely that a main target for the dysregulation of
Th1 effector T cells resulting in a substantial decrease in
Th1 effector fate decision and a concomitant increase in Th2
cells would involve dysregulation of the master transcriptional
regulator, T-bet. However, IRF5 does not play a role in the direct
transcriptional regulation of this key transcription factor (45).
This does not preclude the possibility that IRF5 interacts with Tbet on a protein level. In the following paragraphs, we propose a
novel DEF6-IRF5-T-bet regulatory mechanism that controls Th1
effector T cell polarization.
The SWEF family of Rho-GTPase regulatory proteins consists
of two family members, switching B cell complex subunit
(SWAP70) and DEF6 (also known as IRF4 binding protein,
IBP, or SWAP70-like adaptor of T cells, SLAT) (46, 47). Recent
publications have shown that SWAP70 and DEF6 (also recently
identified as a potential risk variant in human SLE) bind to and
sequester IRF5 in the nucleus of age-associated B cells (ABCs)
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FIGURE 1 | Proposed model for the T cell-intrinsic role of IRF5 as a positive regulator of Th1 effector function and differentiation. (1) IFN-γ stimulation of the IFN-γR on
naïve CD4+ T cells induces STAT1 activation and nuclear translocation. (2) Phosphorylated STAT1 activates the transcription of TBX21, leading to the production of
T-bet. (3) T cell stimulation, possibly through TLR signaling, induces IRF5 activation and nuclear translocation. (4) Nuclear IRF5 recruits T-bet to the silenced IFNG
locus to facilitate permissive T-bet-mediated chromatin remodeling. (5) DEF6 binds to nuclear IRF5 in order to inhibit IRF5-mediated T-bet recruitment to the IFNG
locus. (6) IL-12 signaling through the IL-12R results in STAT4 activation and nuclear translocation. (7) Phosphorylated STAT4 and T-bet induce the transcription of the
accessible IFNG locus and subsequent IFN-γ signaling drives Th1 effector differentiation. (8) T-bet also acts as a positive regulator of RUNX3 transcription. (9) T-bet
interacts with RUNX3 and GATA3 to inhibit the transcription of Th2 signature genes, including IL4, IL5, and IL13, to promote Th1 polarization.

transcriptional program, leading to a defect in Th1 effector
subset polarization, as seen in Irf5 KO models. In addition,
dysregulation of DEF6 could directly impact regulation of the
key Th1 transcriptional driver, T-bet, providing a mechanism by
which DEF6 polymorphisms contribute to SLE risk (Figure 1).

Th2 differentiation, providing additional evidence for this theory.
GATA3 is only downregulated upon initiation of T effector cell
polarization into alternative subsets (61, 63).
Upon initiation of Th2 polarization, the principle Th2
cytokine, IL-4, acts in a stimulatory capacity through activation
of STAT6 phosphorylation. Phosphorylated STAT6 increases
the transcription of IL4 and GATA3. GATA3 is both a vital
component of the machinery required for IL4, IL5, and IL13
transcription and is required for the global epigenetic remodeling
needed to achieve Th2 polarization (64). The importance of
GATA3 in Th2 effector differentiation is demonstrated by the
consequences resulting from loss of GATA3. Even in the absence
of the key Th1 cytokines, IFN-γ and IL-12, lack of GATA3 drives
Th1 polarization (65).
Increased chromatin accessibility mediated by GATA3 both
leads to the secretion of the Th2 specific cytokines, IL-4, IL5, and IL-13, and inhibits the production of the Th1 specific
cytokine, IFN-γ. Interestingly, IRF4 has recently been shown
to act as an additional positive regulator of IL4 transcription
during Th2 differentiation (49, 66). IRF4 forms a complex with

Th2 Cells
Th2 effector T cells are involved in the defense against parasitic
infections, allergic reactions and the resolution of chronic
inflammation (60). Unlike the previously discussed Th1 effector
cells, the mechanisms driving Th2 differentiation are still not
fully understood. Dendritic cells are thought to play a distinct
role in supporting Th2 effector decision. However, they are
incapable of producing the key Th2 mediating cytokine, IL-4
(61). Interestingly, IL-4 produced by CD4+ T cells themselves
has been shown to be sufficient in initiating the Th2 response
(62). These findings support the hypothesis that Th2 effector
decision may be a default response in conditions where there
is a lack of stimuli driving other Th effector fates. High levels
of GATA3 expression in naïve CD4+ T cells prime the cells for
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to myeloid differentiation primary response gene 88 (MyD88)
(74). MyD88 acts as a scaffold protein where IRF5 can receive its
post-translational modifications from its interacting modulators.
MyD88 functions downstream of all TLRs except TLR3 (75).
Inhibition of the IRF5-MyD88 interaction by IRF4 results in
attenuation of inflammatory cytokine production downstream of
TLR signaling (48, 74, 76). However, the impact of T cell TLR
signaling on intrinsic CD4+ T cell effector function and the
pathological conditions that result from dysregulation are still by
and large unconfirmed (77, 78).
The main body of research on the impacts that dysfunction
of TLR signaling at the level of MyD88 might have on T
cells examined how loss of MyD88 in upstream signaling cells
(macrophages and dendritic cells) impacted Th2 differentiation.
Little has been done to examine the specific roles and pathways of
TLR signaling in T cells (75, 79). Mounting evidence implicates
the TLR/MyD88 pathway as a potential regulatory mechanism
in the Th1/Th2 effector decision. A study performed using the
B. burgdorferi model of infection in a T cell-specific MyD88
deletion model demonstrated that loss of MyD88 in T cells
results in an intrinsic defect in the Th1 and Th17 response. Th2
effector response was unfortunately not examined (80). However,
an OVA-based murine MyD88−/ - model of asthma showed
significant defects in Th2 effector response upon stimulation
(81). Taking these findings into account, we postulate that
MyD88 plays an intrinsic role in T effector cell differentiation
alongside IRF4. While IRF4 is expressed at high levels in Th2
effector cells, low levels of IRF5 are associated with a Th2
response. In Epstein-Barr Virus (EBV)-infected B cells, IRF4 was
shown to be a negative transcriptional regulator of IRF5 (82). If
IRF5 is no longer transcribed at high enough levels to initiate
a transcriptional response tailoring an alternative T cell fate
through TLR signaling, a Th2 transcriptional profile maintained
by IRF4 through the previously described mechanisms can be
maintained. This theory is supported by the T cell-specific
MyD88 KO. Here, removal of another key player in the IRF5
TLR signaling pathway results in Th2 skewing, akin to the results
seen in the Irf5 KO (80). Along with the conserved expression
of IRF4 and IRF5 and the as of yet undefined mechanism by
which IL-4 is initially regulated, we postulate that a conserved
IRF4/IRF5/MyD88 axis in effector T cells may be playing a role
in IRF5 activation and the skewing between Th1 and Th2 subsets
(Figure 2).
Ikaros is another mediator that plays an important role in
the maintenance of Th2 effector subset decision. Ikaros is a
hematopoietic transcription factor that directly associates with
Th2 regulatory gene loci and is involved in the positive regulation
of Th2 gene expression (69). Ikaros has a binding site in its
promoter region for IRF4, IRF5, and IRF8. In B cells, IRF8 and
IRF5 both bind and regulate the Ikzf1 promoter, IRF8 acts in
an activating capacity while IRF5 acts as an inhibitor. Inhibition
of Ikzf1 transcription by IRF5 allows for the assumption of
B cell antibody class switching to IgG2a/2c (45). Expression
and function of these IRF transcription factors and Ikaros
are conserved in T cells. If IRF5 were to maintain a similar
negative regulatory function for Ikaros as seen in B cells, loss
of IRF5 would allow unimpeded Ikaros activation, resulting in

GATA3 and the chromatin organizer special AT-rich binding
protein 1 (SATB1) in order to bind to the RHS6 sequence
during Th2 differentiation, located ubiquitously throughout the
Th2 cytokine locus. All three of these factors are required in
order for Th2-specific genes to be expressed (67). GATA3 has
also been proposed to act in a positive feedback loop through
the induction of IRF4 (68). The emerging roles of the complex
transcriptional and regulatory networks involving the master
transcription factor and epigenetic modulator, GATA3, are still
being explored.
As in Th1 cells, there are regulatory mechanisms in place
to inhibit the transcription of alternative T effector subset
mediators upon Th2 effector commitment. One of these factors
is the ubiquitous regulator, Ikaros (a hemopoietic-specific zinc
finger protein also known as IKZF1). Regulatory functions
for Ikaros have been implicated in almost all T helper cell
subsets and loss of Ikaros has been shown to be detrimental
in the maintenance of Th2 commitment. In Ikarosnull CD4+
T cells there is general hypoacetylation of the Th2 cytokine
locus, increased IFN-γ production in Th2 polarizing conditions,
decreased production of IL-4, IL-5, and IL-13, decreased GATA3
and c-MAF expression, and increased levels of T-bet and STAT1.
All of these factors result in a skewing from Th2 to Th1
(69). Despite this growing pool of knowledge on the regulatory
mechanisms ascribed to Ikaros, very little is known about the
regulation of Ikaros itself in T cells (60, 70). However, a recent
study of Ikaros regulation in B cells may provide insight into
a conserved IRF5-dependent Ikaros regulatory mechanism in T
cells (45).

A Conserved MyD88/IRF4/IRF5 and Ikaros
Regulatory Mechanism Mediates the
Th1-Th2 Balance
As previously discussed, the regulation of Th2 cells, and thus the
closely related Th1 effector subset, is still not fully understood.
Pathologic skewing toward a Th2 response has been shown
to result in atopic disorders, such as systemic sclerosis, and
immunosuppression through the dysregulated production of
their hallmark cytokines, IL-4, IL-5, IL-6, IL-9, IL-10, and IL13 (40). IL-4, IL-10, and IL-4-induced IL-10 production in
particular, has an inhibitory role on Th1 effector cells, thereby
further contributing to the skewing from a Th1 to a Th2
phenotype and mediation of Th1 effector response (71, 72). Here
we will explore a potential role for IRF5 in the control of Th2
subsets and how dysregulation can contribute to an enhanced
pathogenic Th1 effector response.
A key role for IRF4 in Th2 subset development and, more
specifically, the control of IL-4 production, has previously been
identified (73). Although the precise regulatory mechanisms at
play for IRF4 in T cells have yet to be fully elucidated, levels of
IRF4 have been shown to be higher in resting Th2 cells compared
to Th1 and Th17 (49). Inquiries into the role of IRF5 in other
immune cell types have revealed alternative roles for IRF4 outside
that of direct transcriptional regulation. In macrophages, IRF4
has been established as a negative regulator of Toll-like receptor
(TLR) signaling by directly competing with IRF5 for binding
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FIGURE 2 | Proposed model for the T cell-intrinsic role of IRF5 as a negative regulator of Th2 effector function and differentiation. (1) Antigenic stimulation of the TCR
induces the upregulation of IRF4, which acts as a repressor of IRF5 transcription. (2) Stimulation of the IL-4R by IL-4 on naïve CD4+ T cells induces STAT6 activation
and nuclear translocation. (3) Phosphorylated STAT6 synergizes with IRF4 to activate GATA3 transcription. (4) A positive regulatory loop supported by
GATA3-mediated IRF4 transcription augments Th2 polarization. (5) GATA3 induces permissive chromatin remodeling at the IL4, IL5, and lL13 Th2 cytokine locus. (6)
IRF4 inhibits the TLR-induced activation of IRF5 via antagonizing the interaction between MyD88 and IRF5. (7) Nuclear IRF5 functions as a negative regulator of IKZF1
transcription, which limits the production of Ikaros. (8) Ikaros and GATA3 promote the transcription of accessible Th2 polarizing genes including IL4, IL5, and IL13. (9)
Ikaros and GATA3 further reinforce the Th2 phenotype via repression of the Th1 transcriptional network.

SLE, MS, psoriasis and cancer (20, 83, 84). Although Th17
effector subsets have been considered for drug targets to
counteract the dysfunctional immune systems that they
help to support, our lack of knowledge about the pathways
regulating the polarization of these cells toward pathogenic
phenotypes has hindered our choice(s) of a specific target
(83). Recently, the monoclonal antibody against IL-17R,
marketed under the name Brodalumab (AMG827), has entered
clinical trials and was shown to be effective in improving
psoriasis (85). However, many other drugs on the market
attempting to initiate an IL-17 blockade have been met with
mixed results depending on the disease setting (86). Thus,
although Th17 effector function is strongly implicated as
a potential target for future drug development, we need to
gain a better understanding of the mechanisms controlling
Th17 pathologic phenotypes and how these can drive
autoimmune disease.
In SLE patients, it has been shown that hyperactive IRF5
results in skewing toward a Th1 and Th17 phenotype. However,
to say simply “Th17 phenotype” is an oversimplification of the

a shift toward Th2 effector polarization. On the other hand,
overexpression or hyperactivation of IRF5, as seen in SLE
patients, could lead to loss of Ikaros transcription and a shift from
the Th2 to Th1 effector T cell subset. In support of this theory,
Gene Ontology shows that IKZF1 has distal sites for T-bet and
GATA3 binding (37). As previously discussed, we postulate that
there is likely a role for IRF5 in the regulation of T-bet through
direct interaction, as well as one for GATA3, by extension
(Figure 2). Thus, there is increasing circumstantial evidence of
a regulatory role for IRF5 in the control of Ikaros function, either
through direct binding or through the recruitment of chromatin
remodeling agents.

Th17 Cells
T cell development is highly dependent on the surrounding
cytokine environment and is characterized by high degrees
of plasticity which, in many cases, can serve a pathogenic
role. This is especially seen in the case of dysregulated Th17
cells, which have been associated with many immunological
diseases including RA, inflammatory bowel disease (IBD),
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IL-17-initiated positive feedback loop from defective Th17 cells
(94, 95).

diversity of this particular T cell subset. Th17 effector T cells
exist in a gradient between classical and pathogenic which is
determined in part by the cytokine milieu they are exposed to. In
the pathogenic state, there are two opposing directions that Th17
cells can follow—either toward a Th1-like phenotype, which is
often associated with autoimmunity or toward a more Th2-like
state, which is correlated with enhanced immunosuppression
(83). At steady state, Th17 cells differentiate into Tfh cells and
support immunoglobulin A (IgA) production by germinal center
B cells. IL-23 in particular, although not required for Th17
differentiation, is required for pathogenic Th17 maintenance and
survival (87).
IL-17A, the “pathogenic” cytokine produced by Th17 cells,
has been shown to be a key player in the perpetuation of
inflammation associated with autoimmune tissue damage.
IL-17A functions through several mechanisms including
the activation of other immune cells, increasing B cell
functions, recruiting neutrophils, Treg mediation and enhancing
proinflammatory cytokine release (20, 88, 89). In the mouse
model of human MS (murine experimental autoimmune
encephalomyelitis, EAE), blocking the interaction between
IL-17 and IL-17 receptors resulted in substantial attenuation of
EAE development (90). Unfortunately, the picture painted by
this interaction is oversimplified. To date, there have been six
different IL-17 cytokines identified, IL-17A–F, and five unique
versions of the IL-17 receptor, IL-17RA–RE. For a more extensive
review on what is known about the functional variations of these
family members, see Swaidani et al. (91) and Jin and Dong
(92). Although IL-17A has been identified as the main mediator
of inflammation associated with autoimmune disease, the
pathways downstream of IL-17A binding to IL-17R are still not
fully defined.
In non-disease states, Th17 cells serve an important function
in supporting tailored immune responses to various pathogens
(20). Th17 effector cells maintain a balance between the
alternative Treg differentiation pathway and conversion into a
Th1-like phenotype. IRF4 has been shown to be a key mediating
factor in maintaining the balance between Th17 and Tregs.
Irf4 KO results in an increase in the Treg FoxP3 (forkhead
box P3) transcription factor and a decrease in RORγt (RARrelated orphan receptor gamma t), the major transcription factor
for commitment to Th17 fate in part through transcriptional
upregulation of IL-17 (93). The relatively one-sided conversion
from Th17 to Th1 seems to be controlled through stimulation
from circulating cytokines. Stimulation of Th17 polarized cells
by IL-12 and IFN-γ results in inhibition of IL-17 secretion and
conversion to a more Th1-like state, characterized by increased
levels of STAT4 and T-bet expression. Increased levels of TGF-β
inhibit this plasticity and result in maintenance of a stable Th17
phenotype. Early STAT transcription factors are also at play in the
regulation of Th17 decision; STAT3 promotes and STAT5 inhibits
Th17 differentiation (23). Because of the plasticity of the Th17
subset and its ability to interconvert between many other effectorlike subsets in response to disease, the regulation of this particular
subset is complex and still not well-understood. However, it has
been established that maintenance of the inflammatory state that
characterizes many autoimmune diseases is in part due to the
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A Potential IRF5-Mediated T Cell-Intrinsic
Feedback Loop Regulates the Th17
Effector Decision Through Inflammatory
Cytokine Production, STAT3, Ikaros and
IL-10
The role of IRF5 in Th17 effector cells is still an open
field. However, based on the previous mechanisms described,
especially those relating to Th1 regulation, a role for IRF5 in Th17
differentiation and plasticity seems highly likely. Several studies
have supported a role for IRF5 in Th17 effector differentiation,
although few, if any, studies have yet to examine an intrinsic
role for IRF5 in Th17 cells. Loss of Irf5 in murine models of
severe asthma resulted in decreased IFN-γ and IL-17 responses
upon ovalbumin (OVA) immunization (96). In an Irf5 KO
antigen-induced arthritis (AIA) model, Th1, Th17, and γδ IL17 producing T cells were found to have significantly decreased
effector responses following immunization with methylated
bovine serum albumin (mBSA) in complete Freund’s adjuvant
(CFA). In addition, this model showed decreased levels of Ifng
and Il17a mRNA and the key Th1 and Th17 cytokines IL-1β, IL-6,
IL-12, and IL-23 (97).
The cytokines that are often used to characterize proinflammatory Th17 subsets are IL-22, GM-CSF, and IFN-γ.
Interestingly, several of these inflammatory cytokine mediators
are also known to induce the expression of IRF5. In macrophages,
increased IRF5 expression results in an M1 (inflammatory)
macrophage phenotype through the upregulation of IL-12,
TNF-α, and IFN-γ, with concomitant repression of IL-10
(98). Through binding to various promoter regions, IRF5 also
increases IL6, IL12, and IL23p19 transcription. Interestingly,
pathogenic Th17 cells also secrete IL-12, IL-23, IL-6, and IFNγ in addition to various other Th17-specific effector cytokines
and transcription factors (66, 99). A conserved role for IRF5 in
the transcriptional activation of these inflammatory cytokines in
Th17 cells should be explored.
IL-10 production by Th17 cells may provide yet another
avenue for a potential role for IRF5 in the regulation of
Th17-mediated inflammation (100). Although the regulation
of IL-10 in Th17 effector cells is not fully understood, it
has been well-established that IL-10 is required for T cells to
maintain control over Th17 effector function (101). One of the
mechanisms by which IL-10 expression is mediated is through
TGF-β and IL-6. These two factors work to activate the c-MAF
transcription factor through STAT3, which in turn activates IL10
transcription by binding to the IL10 promoter (102). IL-10 acts to
reduce IL-17 and IFN-γ production, thus negatively regulating
pro-inflammatory Th17 effector reactions. Interestingly, in the
context of Newcastle disease virus (NDV)-infected Balb-C mice,
IRF5 was shown to induce Stat3 transcription in the presence
of undetectable levels of the cytokines IL-6 and IL-10 (103).
In addition, IRF5 has been shown to be a key mediator
of IL6 transcription in human pDCs (104). IRF5 was also
shown to be upregulated by the janus kinase 2 (JAK2)/STAT3
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pathway in human umbilical vein endothelial cells (105). The
existence of a positive feedback loop between STAT3 and
IRF5 in Th17 cells, where activation of IRF5 transcription
downstream of STAT3 allows for IRF5 to feedback and increase
IL-6 and STAT3 expression, should be explored as a potential
mechanism by which IRF5 mediates Th17 effector response
(Figure 3).
In an alternative regulatory arm, Ikaros has been shown
to be required for inhibition of heterochromatic remodeling
at the gene loci for the Th17 effector program. Ikaros has
also been shown to repress expression of both FOXP3 and
TBX21, which both normally act to negatively regulate Th17
development (106, 107). However, T-bet was also reported
to positively regulate transcription of the IL23R by binding
to a specific site in the IL23R promoter sequence and
inducing IFN-γ expression by Th17 cells, thus inducing a
pro-inflammatory state (108, 109). Hence, depending on the
location and context of T-bet expression in Th17 cells, Tbet can initiate or ameliorate inflammatory responses. The
precise mechanisms through which these regulatory actions are

achieved have not yet been established. In addition to binding
to and regulating FOXP3 and TBX21 expression, Ikaros has
a binding site specifically within the IL10 promoter and acts
to positively regulate IL-10 production. It is likely that Ikaros
has other, as of yet, undefined epigenetic and transcriptional
regulatory roles to support Th17 effector functions (106, 110).
A hint as to additional regulatory mechanisms involved in
the pathways leading to Th17 effector commitment comes
through literature on IRF5 regulation. In macrophages, IRF5
has been shown to have both positive and negative effects on
IL10 transcription through direct binding to the IL10 promoter
(98, 111). In Th17 cells, IL-10 plays a crucial role in the
downregulation of the pro-inflammatory cytokines, IL-17 and
IFN-γ. As loss of IRF5 results in a decrease in Th17 effector
subsets, this could imply a positive regulatory role for IRF5
in a conserved pathway, either through an inhibitory role at
the IL10 promoter (as seen in macrophages), a negative role
in Ikaros regulation (as described in B cells) or induction of
a STAT3–IRF5 positive feedback loop as previously described
(Figure 3).

FIGURE 3 | Proposed model for the T cell-intrinsic role of IRF5 as a positive regulator of Th17 effector function and differentiation. (1) Stimulation of the IL-6R/gp130
complex by IL-6 on naïve CD4+ T cells induces STAT3 activation and nuclear translocation. (2) Phosphorylated STAT3 induces the transcription of RORC, leading to
the production of RORγt. (3) Antigenic stimulation of the TCR induces the upregulation of IRF4. (4) RORγt induces the transcription of IL17A, driving Th17-mediated
inflammation. (5) The transcription of IRF5 is positively regulated by phosphorylated STAT3 and negatively regulated by IRF4. (6) IRF4 inhibits the TLR-induced
activation of IRF5 via antagonizing the interaction between MyD88 and IRF5. (7A–D) Nuclear IRF5 promotes the Th17 phenotype through upregulation of IL6 (7A) and
STAT3 (7B) expression and repression of IKZF1 (7C) and IL10 (7D) transcription. (8) Ikaros functions as a positive regulator of IL10 transcription. (9) IL-10 signaling
through the IL-10R antagonizes the production of IL-17A, thereby inhibiting Th17 inflammatory responses.
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CONCLUSION

severity of the disease is determined by the addition of other
risk allelic variations, thereby leading to the unique signature
characterizing individual autoimmune conditions. This also
explains the as-of-yet undefined and heterogeneous pathwayspecific triggers that lead to disease development in a perfect
storm of self-perpetuating dysregulated pathway activation,
characterized by aberrant cytokine production. Ultimately, the
goal in effective therapeutic development is to find the most
specific target that ameliorates the greatest number of disease
phenotypes with the fewest off-target effects. In order to
accomplish this, we need a detailed understanding of the
pathways that govern each immune cell implicated in disease
pathogenesis. Targeting the inflammatory cytokines themselves
is a difficult and non-specific therapeutic option, although early
clinical trials of low dose IL-2 administration have shown
some promise in patients with treatment-resistant SLE (113).
However, the list of “T cell” therapeutics for autoimmune
disease is brief, and many of them [i.e., secukinumab,
ixekizumab, broalumab, ustekinumab, iberdomide, AMG 570
targeting ICOS-L (NCT04058028)] have either yet to be
proven efficacious in the treatment of SLE, are still in
early clinical trials, or broadly target the functions of other
immune cells (114–116). As a result, targeted delivery of
therapeutic molecules to specific immune cell subsets that drive
the dysregulated release of either pro-or anti-inflammatory
cytokines is the future of effective personalized treatments for
autoimmune disease.

The role and relevance of IRF5 in immune cell dysfunction
in the context of autoimmune disease and cancer progression
has become a hot topic for research in recent years. However,
despite our growing knowledge of functions for IRF5 in APCs,
our knowledge on the role of T cell-intrinsic IRF5 function
is still lacking. Most of the literature published on potential
roles for IRF5 in T cells is confounded by the dysregulation
of other upstream immune cell signaling pathways in the in
vivo setting of an Irf5−/− mouse. The CD4+ T cell-specific
Irf5 KO model attempted to address this and, in the context
of CD3/CD28 TCR stimulation with IL-12, showed no defects
in IFN-γ production (54). However, preliminary work from
our lab utilizing RAG2−/− mice as recipients of Irf5+/+ and
Irf5−/− T cells reveals a stimulus-dependent T cell-intrinsic
defect that drives aberrant immune cell responses which, in the
context of the hypothesized TLR driven IRF5 pathways in T
cells, rather than rejecting previous work, compliments their
findings (data not shown). The generation and characterization
of new T cell-specific conditional Irf5 KO mice, combined
with pathway-specific immune challenges, will help to delineate
Irf5 intrinsic function in T cells. For example, to study an
intrinsic role for Irf5 in Th17 cells, Irf5-floxed mice would be
crossed to IL17(A/F)-cre mice to generate Th17-specific Irf5
conditional KO mice. A number of T cell-specific cre-reporter
strains are currently available that would help prove or disprove
the presented hypotheses.
In the clinical realm, SLE is characterized by a heterogeneous
patient population. In each patient, the disease shares several
common characteristics, but ultimately has a unique landscape
and response to treatment. This is likely driven by a
“multi-hit” scenario where dysfunction or dysregulation of a
single (or multiple) master regulatory factor, like IRF5, will
predispose individuals to developing a specific brand of immune
dysregulation with many shared pathological characteristics
(112). However, ultimately the path of development and resulting
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